Reading Your Child's Lab and Genetic Reports
At a Glance
In CMO II deficiency, a child’s tests often show low sodium, high potassium, metabolic acidosis, high renin, and low or inappropriately normal aldosterone. Elevated 18-hydroxycorticosterone and CYP11B2 testing can support the diagnosis, but results need pediatric specialist interpretation.
Reading your child’s lab reports can feel like learning a new language. These reports contain the “biochemical fingerprint” of Corticosterone Methyloxidase Type 2 (CMO II) deficiency [1]. Because this condition is rare, the values on the page must be interpreted carefully by a pediatric endocrinologist who understands how infant bodies handle salt differently than adults [2].
The Core Electrolyte Panel
The first labs you likely saw were basic electrolytes. In a child with untreated CMO II, these typically show a specific pattern:
- Sodium (Hyponatremia): Levels are usually low because the kidneys are “wasting” salt in the urine [3].
- Potassium (Hyperkalemia): Levels are often high because the body cannot get rid of extra potassium without aldosterone [1].
- Bicarbonate/pH: Reports may show “metabolic acidosis,” meaning the blood is more acidic than it should be due to the electrolyte imbalance [1][4].
The Hormone “Tug-of-War”
To help diagnose the condition, doctors look at the relationship between two main hormones: renin and aldosterone.
- Renin: This is a “messenger” hormone that tells the body to make more aldosterone [1]. In CMO II, renin is usually elevated, sometimes markedly elevated, because the body is desperately signaling for more salt [1].
- Aldosterone: Despite the high renin signal, aldosterone levels will be low or “inappropriately normal” [3]. In a healthy infant with such high renin, the aldosterone should be sky-high. If it is only “normal,” it points to a problem with the adrenal gland [5][6].
Specialized Markers: 18-Hydroxycorticosterone
The “Type II” in CMO II refers to where the production line is blocked. In this specific deficiency, the body can make the “precursor” (building block) but cannot finish the job [7].
- 18-hydroxycorticosterone: This is the precursor molecule. In CMO II, it often builds up to very high levels in the blood and urine [7].
- The Ratio: Doctors don’t just look at this marker alone; they look at the ratio of 18-hydroxycorticosterone to aldosterone. A high ratio supports the diagnosis that the enzyme (aldosterone synthase) is failing at the very last step [7][8]. Keep in mind that ratios can fluctuate based on age, posture, and sodium status, so they are not standalone confirmations.
Genetic Testing: The “Twin Gene” Challenge
Testing the CYP11B2 gene can help establish a molecular diagnosis [9]. However, these reports can be tricky because of a biological quirk: the CYP11B2 gene (which makes aldosterone) is roughly 95% identical to a nearby “twin” gene called CYP11B1 (which makes cortisol) [9][10].
Because they look so similar, standard genetic testing methods can sometimes struggle to tell them apart. Laboratories often have to use specialized techniques (like “selective amplification”) to ensure they are looking at the correct gene [9]. Your genetic counselor or endocrinologist will interpret these results alongside the biochemical tests; a negative or uncertain genetic result does not necessarily rule out the condition if the blood and urine markers strongly point to it [11].
For Families Who Want More Detail
When reviewing your child’s records with your doctor, you might encounter these technical terms:
- LC-MS/MS: A highly accurate method (Liquid Chromatography with Tandem Mass Spectrometry) used to measure aldosterone. It is generally preferred over older “immunoassay” methods [12][7].
- PRA vs. DRC: Renin can be measured as “Plasma Renin Activity” (PRA) or “Direct Renin Concentration” (DRC). Both are valid but use different scales [1].
- Cortisol: While a single, random cortisol level being normal is a good sign, it is not a complete assessment of the body’s “cortisol reserve.” [3].
Common questions in this guide
What lab pattern is common in a child with CMO II deficiency?
What does a high 18-hydroxycorticosterone-to-aldosterone ratio mean?
Can a normal aldosterone result rule out CMO II deficiency in an infant?
Why can CYP11B2 genetic testing be difficult to interpret?
Can salt supplements or medicines change my child's test results?
What other tests might appear in a CMO II deficiency report?
Get notified when new evidence is published on corticosterone methyloxidase type 2 deficiency.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (12)
- 1
Congenital aldosterone deficiency and its resistance.
Tajima T, Amano N, Ishii T, et al.
Endocrine journal 2026; (73(6)):751-763 doi:10.1507/endocrj.EJ25-0630.
PMID: 41905953 - 2
Congenital primary adrenal insufficiency and selective aldosterone defects presenting as salt-wasting in infancy: a single center 10-year experience.
Bizzarri C, Olivini N, Pedicelli S, et al.
Italian journal of pediatrics 2016; (42(1)):73 doi:10.1186/s13052-016-0282-3.
PMID: 27485500 - 3
Clinical and Genetic Characteristics of Patients with Corticosterone Methyloxidase Deficiency Type 2: Novel Mutations in CYP11B2
Turan H, Dağdeviren Çakır A, Özer Y, et al.
Journal of clinical research in pediatric endocrinology 2021; (13(2)):232-238 doi:10.4274/jcrpe.galenos.2020.2019.0216.
PMID: 32539318 - 4
A Novel Mutation of the CYP11B2 in a Saudi Infant with Primary Hypoaldosteronism.
Alfaraidi L, Alfaifi A, Alquaiz R, et al.
Case reports in endocrinology 2017; (2017()):8431475 doi:10.1155/2017/8431475.
PMID: 29201470 - 5
Aldosterone signaling defect in young infants: single-center report and review.
Wijaya M, Ma H, Zhang J, et al.
BMC endocrine disorders 2021; (21(1)):149 doi:10.1186/s12902-021-00811-9.
PMID: 34243750 - 6
Clinical analysis of salt-wasting in infants due to genetic aetiology.
Xie Y, Liu X, Tang J, Lan D
Endokrynologia Polska 2024; (75(6)):684-692 doi:10.5603/ep.101578.
PMID: 40091330 - 7
Deciphering aldosterone deficiency and pseudodeficiency in infancy by targeted GC-MS urinary steroid metabotyping.
Li H, Pons-Kühnemann J, Hartmann MF, Wudy SA
The Journal of steroid biochemistry and molecular biology 2027; (265()):107103 doi:10.1016/j.jsbmb.2026.107103.
PMID: 42603653 - 8
Structural and clinical characterization of CYP11B2 inhibition by dexfadrostat phosphate.
Pignatti E, Kollar J, Hafele E, et al.
The Journal of steroid biochemistry and molecular biology 2023; (235()):106409 doi:10.1016/j.jsbmb.2023.106409.
PMID: 37827219 - 9
Molecular Analysis of the CYP11B2 Gene in 62 Patients with Hypoaldosteronism Due to Aldosterone Synthase Deficiency.
Merakou C, Fylaktou I, Sertedaki A, et al.
The Journal of clinical endocrinology and metabolism 2021; (106(1)):e182-e191 doi:10.1210/clinem/dgaa765.
PMID: 33098647 - 10
GRAde: a long-read sequencing approach to efficiently identifying the CYP11B1/CYP11B2 chimeric form in patients with glucocorticoid-remediable aldosteronism.
Wu YC, Chen CI, Chen PY, et al.
BMC bioinformatics 2022; (22(Suppl 10)):613 doi:10.1186/s12859-022-04561-w.
PMID: 35012455 - 11
Severe Aldosterone Synthase Deficiency in a 9-Day-Old Lebanese Boy: The Importance of Functional Studies to Establish Pathogenicity of Seemingly Benign Variants in CYP11B2.
Ghaddhab C, Capper CP, Larrivée-Vanier S, et al.
Hormone research in paediatrics 2025; (98(1)):96-102 doi:10.1159/000536437.
PMID: 38316111 - 12
Catch-up Growth and Discontinuation of Fludrocortisone Treatment in Aldosterone Synthase Deficiency.
Gurpinar Tosun B, Kendir Demirkol Y, Seven Menevse T, et al.
The Journal of clinical endocrinology and metabolism 2022; (107(1)):e106-e117 doi:10.1210/clinem/dgab619.
PMID: 34415991
This page explains how CMO II lab and genetic results may be interpreted for educational purposes; it does not replace medical advice from your child's pediatric endocrinologist or genetic counselor.